Fostering Drug Discovery with the Significant Increase in the Number of Biobanks During 1970-2010
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Fostering Drug Discovery with the Significant Increase in the Number of Biobanks During 1970-2010 Biobanks have recently been developed under the support of public or private initiatives as suitable tools for biomedical research purposes. The number of biobanks significantly increased during 1989-1999, with significant percentage increase in the 1990s. The majority of biobanks are formed as an integral part of a university to facilitate research and also to provide samples to external researchers. This report provides in-depth study of 40 major biobanks, with analysis of biobanking funding structure and volume of sample sizes in the biobanks, with a major focus on issues concerning biobanks. The Majority of Issues Affecting the Growth of Biobanks are Common to all Biobanks The availability of a specific type of sample and a particular mode of storage are some of the common issues in biobanks. A tumor tissue repository (TTR) is a source of brain tumor samples, which suffers from the problem of the unavailability of normal brain samples to use as controls during studies. The situation is similar in other types of biobank. Comparative studies are increasingly difficult due to the unavailability of negative samples such as controls.
Sample storage also plays a vital role in each biobank. Among the various ways to store tissue, such as formalin fixed, paraffin embedded blocks and snap frozen samples, frozen tissue is always in significant demand and so preserving tissue via this method is popular. Stand-Alone Biobanks Outline Strength of the Biobanking Sector In a comparative study of more than 100 biobanks around the world, many biobanks are found to be stand-alone, with the whole funding received by the government of the country. Around 70% of biobanks are stand-alone, whereas only 30% are partnered with other biobanks or institutions. In total, biobanks are 39% national or regional biobanks, 39% universities, 19% non-profit foundations, and only 3% private. With 39% each, national biobanks and universities play a major role in this sector, while non-profit foundations generally suffer from funding problems, as there is no continuous source of income. The private sector is comparably small and mostly confined to the biobanks associated market, which includes equipment, liquid storage, and so on. GBI Research, the leading business intelligence provider, has released its latest research, “Biobanks – 2011 Yearbook”. It provides key data, information and
analysis of the 40 major biobanks in the world. The report provides information on the population-based biobanks, disease based biobanks, brain biobanks, stem cell biobanking, twin registries, children biobanks and many national biobanks. This report provides comprehensive analysis of funding, harmonization, cost of biobanking, and partnership structure. It also reviews the factors determining the success and failure of the biobanks. It is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts For further details, please click or add the below link to your browser: http://www.gbiresearch.com/Report.aspx?ID=Biobanks-2011-Yearbook&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Visit our report store: http://www.gbiresearch.com
For more details contact: firstname.lastname@example.org North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782